Lexicon Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($1.55) Per Share (LXRX)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Research analysts at Gabelli raised their FY2017 EPS estimates for Lexicon Pharmaceuticals in a note issued to investors on Thursday. Gabelli analyst K. Kedra now forecasts that the biopharmaceutical company will post earnings of ($1.55) per share for the year, up from their prior forecast of ($1.65).

Several other analysts have also issued reports on LXRX. Zacks Investment Research lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 17th. Needham & Company LLC reissued a “buy” rating on shares of Lexicon Pharmaceuticals in a report on Friday, January 27th. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Lexicon Pharmaceuticals in a report on Wednesday, February 8th. HC Wainwright reissued a “buy” rating and set a $27.00 target price (up from $26.00) on shares of Lexicon Pharmaceuticals in a report on Wednesday, March 1st. Finally, Citigroup Inc increased their target price on Lexicon Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, March 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $26.67.

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

TRADEMARK VIOLATION WARNING: “Lexicon Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($1.55) Per Share (LXRX)” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.themarketsdaily.com/2017/05/20/lexicon-pharmaceuticals-inc-forecasted-to-earn-fy2017-earnings-of-1-55-per-share-lxrx-updated.html.

Lexicon Pharmaceuticals (NASDAQ:LXRX) traded down 0.50% during midday trading on Monday, reaching $15.80. 57,391 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $14.83 and a 200 day moving average price of $15.14. Lexicon Pharmaceuticals has a 12 month low of $11.52 and a 12 month high of $19.62. The company’s market cap is $1.66 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Friday, March 3rd. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.20. Lexicon Pharmaceuticals had a negative net margin of 11.87% and a negative return on equity of 9.46%. The firm had revenue of $23 million for the quarter, compared to the consensus estimate of $15.56 million. During the same quarter in the previous year, the company earned $0.76 earnings per share. The business’s revenue was down 81.9% compared to the same quarter last year.

A number of hedge funds have recently added to or reduced their stakes in LXRX. State Street Corp raised its stake in Lexicon Pharmaceuticals by 17.2% in the fourth quarter. State Street Corp now owns 1,591,365 shares of the biopharmaceutical company’s stock valued at $22,008,000 after buying an additional 233,371 shares during the period. Russell Investments Group Ltd. purchased a new position in Lexicon Pharmaceuticals during the fourth quarter valued at approximately $1,242,000. Candriam Luxembourg S.C.A. increased its position in Lexicon Pharmaceuticals by 52.3% in the third quarter. Candriam Luxembourg S.C.A. now owns 195,000 shares of the biopharmaceutical company’s stock valued at $3,524,000 after buying an additional 67,000 shares in the last quarter. D. E. Shaw & Co. Inc. increased its position in Lexicon Pharmaceuticals by 238.1% in the third quarter. D. E. Shaw & Co. Inc. now owns 667,130 shares of the biopharmaceutical company’s stock valued at $12,055,000 after buying an additional 469,827 shares in the last quarter. Finally, HBK Investments L P purchased a new position in Lexicon Pharmaceuticals during the third quarter valued at approximately $1,263,000.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

5 Day Chart for NASDAQ:LXRX

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply